SHORT TITLE: C1973-204

RESEARCH PROTOCOL TITLE: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction

PRINCIPAL INVESTIGATOR: Jaya Krishna, MD

RESEARCH SPONSOR: Ironwood Pharmaceuticals, Inc.

Clinical Trials.Gov Listing at:

STUDY PURPOSE
This purpose of this study is to test the safety of an investigational drug, IW-1973, compared to a placebo, and its effect on the ability to exercise after being taken for 12 weeks, in patients with Heart Failure with a preserved ejection fraction.

STUDY PROCEDURES
There will up to 8 visits over 13 weeks. Visits may include blood tests, physical exams, vital signs, cardiac metabolic testing, questionnaires and dispensing of investigational medication.

ELIGIBILITY CRITERIA FOR SUBJECTS
Must be able and willing to give informed consent
Ambulatory male or female equal to or greater than 50 years of age
Has Heart Failure with an Ejection Fraction equal to or greater than 45%

SUBJECT PAYMENT
Subjects will be compensated $50 for each completed study visit.

RESEARCH LOCATION AND CONTACT PERSON
Amanda Gessler
UnityPoint Health-Meriter-Heart & Vascular Institute
2601 West Beltline Hwy.
Suite 200
Madison, WI 53713

PHONE: 608-417-2168